«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2021 04

Page:

609-615

Research Field:

Publishing date:

Info

Title:

Bioinformatics analysis of differential genes in breast cancer bone metastases

Author(s):

LIU Siqi¹; SUN Xin¹; XU Xiaohui¹; LIN Fangcai²

1.Department of Breast Surgery;2.Department of General Surgery,Capital Medical University Electric Power Teaching Hospital,Beijing 100071,China.

Keywords:

breast cancer bone metastasis; differentially expressed genes; prognosis; therapeutic target

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2021.04.014

Abstract:

Objective£ºTo find the potential therapeutic targets and prognostic predictor by digging and screening differentially expressed genes (DEGs) for breast cancer bone metastasis in bioinformatics databases,and the cell location,molecular function and potential molecular mechanisms of DEGs were explored.Methods:By screening and downloading breast cancer bone metastasis-related expression profiles in the Gene Expression Omnibus (GEO),RStudio was used to evaluate the quality of these profiles,select differentially expressed genes (DEGs),draw heat maps and volcano maps.Finally,Gene Ontology (GO) functional annotation and Kaplan Meier Plotter were performed respectively.Results:After screening GSE137842 and GSE51232,44 common DEGs were obtained,including 34 downregulated DEGs and 10 upregulated DEGs.A total of 18 related DEGs were obtained through GO enrichment analysis and survival analysis.GO enrichment analysis revealed that related molecular functions were mainly concentrated in ligase activity,including downregulated genes ZNRF3,RNF182,and UHRF1.Biological processes were mainly concentrated in the process of apoptosis and vascular endothelial growth factor receptor signaling pathways,involving a total of 3 upregulated genes ELMO1,SULF1,and DAPK1.After the survival analysis by Kaplan Meier Plotter online analysis tool,12 DEGs consistent with gene expression and closely related to relapse-free survival (RFS) or overall survival (OS) were all down-regulated genes.A total of 16 related DEGs were obtained through GO enrichment analysis and survival analysis.Conclusion:The 16 DEGs obtained by GO enrichment analysis and survival analysis are ELMO1,SULF1,DAPK1,UHRF1,TOX2,BMPR1B,NXPE3,AEBP2,ADIPOR2,GPR63,ZNRF3,NECAP1,SLAIN1,MICB,POPDC3,ALKBH6 can be used as treatment targets and 12 DEGs obtained by survival analysis can be used as prognostic indicators for breast cancer patients with bone metastasis including TOX2,BMPR1B,NXPE3,AEBP2,ADIPOR2,GPR63,ZNRF3,NECAP1,SLAIN1,MICB,POPDC3,ALKBH6.

References:

£Û1£ÝBRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA:Cancer Journal for Clinicians,2018,68(6):394-424.
£Û2£Ý³ÂÍòÇà,Ëï¿ÉÐÀ,Ö£ÈÙÊÙ,µÈ.2014ÄêÖйú·ÖµØÇø¶ñÐÔÖ×Áö·¢²¡ºÍËÀÍö·ÖÎö£ÛJ£Ý.ÖлªÖ×ÁöÔÓÖ¾,2018,27(1):1-14. CHEN WQ,SUN KX,ZHENG RS,et al.Report of cancer incidence and mortality in different areas of China,2014£ÛJ£Ý.Bulletin of Chinese Cancer,2018£¬27(1):1-14.
£Û3£ÝÖ£ÈÙÊÙ,Ëï¿ÉÐÀ,ÕÅ˼ά,µÈ,2015ÄêÖйú¶ñÐÔÖ×ÁöÁ÷ÐÐÇé¿ö·ÖÎö£ÛJ£Ý.ÖлªÖ×ÁöÔÓÖ¾,2019£¬41(1):19-28. ZHENG SR,SUN KX,ZHANG SW,et al.Report of cancer epidemiology in China,2015£ÛJ£Ý.Chin J Oncol,2019,41(1):19-28.
£Û4£Ý³ÂÀòÀò£¬Ê¯¾Õ·¼£¬ÁõÓñÇÙ£¬µÈ.»ùÓÚÈËȺµÄÈéÏÙ°©Ô¤ºó²ÎÊýÑо¿ÏÖ×´£ÛJ£Ý.ÖлªÈéÏÙ²¡ÔÓÖ¾£¨µç×Ӱ棩,2018£¬12(6):370-372. CHEN LL,SHI JF,LIU YQ,et al.Population-based prognostic parameters of breast cancer£ÛJ£Ý.Chinese Journal of Breast Disease (Electronic Version),2018,12(6):370-372.
£Û5£ÝSJ L,PARK S,AHN HK,et al.Implications of bone-only metastases in breast cancer:favorable preference with excellent outcomes of hormone receptor positive breast cancer£ÛJ£Ý.Cancer Research Treatment,2011,43(2):89-95.
£Û6£ÝRUCCI N,SANIT¦D P,MONACHE SD,et al.Molecular pathogenesis of bone metastases in breast cancer:Proven and emerging therapeutic targets£ÛJ£Ý.World Journal of Clinical Oncology,2014,5(03):335-347.
£Û7£ÝWOOLF DK,PADHANI AR,MAKRIS A.Assessing response to treatment of bone metastases from breast cancer:What should be the standard of care£ÛJ£Ý.Ann Oncol,2015,26(6):1048-1057.
£Û8£Ý½­Ôó·É.ÈéÏÙ°©¹ÇתÒƺ͹ÇÏà¹Ø¼²²¡ÁÙ´²ÕïÁÆר¼Ò¹²Ê¶£¨2014°æ£©£ÛJ£Ý.ÖлªÒ½Ñ§ÔÓÖ¾£¬2015£¬12(4):241-247. JIANG ZF.Expert consensus on clinical diagnosis and treatment of breast cancer bone metastases and bone-related diseases (2014 version) £ÛJ£Ý.National Medical Journal of China,2015,12(4):241-247.
£Û9£ÝÔø»Û¾ê,ÍõÉÙ»ª.ÈéÏÙ°©¹ÇתÒÆ·Ö×Ó»úÖÆÑо¿½øÕ¹£ÛJ£Ý.ҽѧÑо¿Éúѧ±¨£¬2015£¬28(04):432-436. ZENG HJ,WANG SH.Research progress on the molecular mechanism of breast cancer bone metastasis£ÛJ£Ý.Bulletin of Medical Postgraduate,2015,28(04):432-436.
£Û10£ÝGREAVES M,MALEY CC.Clonal evolution in cancer£ÛJ£Ý.Nature,2012£¬481(7381):306-313.
£Û11£ÝL¦BNCZKY A,NAEY ¦B,BOTTAI G,et al.miRpower:A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients£ÛJ£Ý.Breast Cancer Research,2016,160(3):439-446.
£Û12£ÝCARTER JA,JI X,BOTTEMAN MF,et al.Clinical,economic and humanistic burdens of skeletal-related events associated with bone metastases£ÛJ£Ý.Expert Review of Pharmacoeconomics Outcomes Research,2013,13(4):483-496.
£Û13£ÝÖÜêÊ»Ô,Ö×ÁöÒÖÖÆÒò×ÓZNRF3ÔÚθÏÙ°©·¢²¡ÖеÄ×÷ÓûúÖÆÑо¿£ÛD£Ý.ËÕÖÝ£ºËÕÖÝ´óѧ,2013. ZHOU YH.The study on tumorgenesis of the tumor suppressor ZNRF3 in gastric adenocarcinoma£ÛD£Ý.Suzhou:Suzhou University,2013.
£Û14£ÝJIN W,LIU Y,XU SG,et al.UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs£ÛJ£Ý.Breast Cancer Research,2010,124(1):39-48.
£Û15£ÝZHAO J,ZHAO D,POAGE GM,et al.Death-associated protein kinase 1 promotes growth of p53-mutant cancers£ÛJ£Ý.The Journal of Clinical Investigation,2015,125(7):2707-2720.
£Û16£ÝLI H,YANG L,FU H,et al.Association between G¦Ái2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis£ÛJ£Ý.Nature Communications,2013,4(7):1706.
£Û17£ÝLIANG Y,WANG S,ZHANG Y.Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway£ÛJ£Ý.Oncology Letters,2018,16(3):3481-3488.
£Û18£ÝMATHEWOS T,CHRISTIN MY,MARCIE JG,et al.Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers£ÛJ£Ý.PLoS One,2017,7(4):e34850.
£Û19£ÝYU X,LI Z.TOX gene:A novel target for human cancer gene therapy£ÛJ£Ý.American Journal of Cancer Research,2015,5(12):2156-2176.
£Û20£ÝHUO Y,SU T,CAI Q,et al.An in vivo gain-of-function screen identifies the Williams-Beuren syndrome gene GTF2IRD1 as a mammary tumor promoter£ÛJ£Ý.Cell Reports,2016,15(10):2211-2247.
£Û21£ÝYAMADA N,YASUI K,DOHI O,et al.Genome-wide DNA methylation analysis in hepatocellular carcinoma£ÛJ£Ý.Oncology Reports,2016,35(4):28-36.
£Û22£ÝZHANG Q,WANG W,GAO Q.¦Â-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer£ÛJ£Ý.Biochemical and Biophysical Research Communications£¬2019,523(1):274-279.
£Û23£ÝQIN H,CAI A,XI H,et al.ZnRF3 induces apoptosis of gastric cancer cells by antagonizing wnt and hedgehog signaling£ÛJ£Ý.Cell Biochemistry Biophysics,2015,73(2):361-367.
£Û24£ÝÁõ°®Þ¥,ÀîÐãÄÏ£¬Íõ¸ÖÀÖ£¬µÈ.Ö¬ÁªËؼ°ÆäÊÜÌåÔÚÈéÏÙ°©Öеıí´ï¼°ÆäÓëÁÙ´²²¡ÀíÌØÕ÷µÄÏà¹ØÐÔ·ÖÎö£ÛJ£Ý.ÏÖ´úÉúÎïҽѧ½øÕ¹,2017,17(17):3285-3290. LIU AH,LI XN,WANG GL,et al.Analysis on expression of adiponectin and its receptors in breast cancer and its correlation with clinicopathological features£ÛJ£Ý.Progress in Modern Biomedicine,2017,17(17):3285-3290.
£Û25£ÝWILKIE GS,KORFALI N,SWANSON SK,et al.Several novel nuclear envelope transmembrane proteins identified in skeletal muscle have cytoskeletal associations£ÛJ£Ý.Molecular Cellular Proteomics,2011,10(1):3121-3127.
£Û26£ÝKORFALI N,WILKIE GS,SWANSON SK,et al.The nuclear envelope proteome differs notably between tissues£ÛJ£Ý.Nucleus,2012,3(6):552-564.
£Û27£ÝAMUNJELA JN,TUCKER SJ.POPDC proteins as potential novel therapeutic targets in cancer£ÛJ£Ý.Drug Discovery Today,2016,21(12):1920-1927.

Memo

Memo:

¹ú¼ÒµçÍø¹«Ë¾¿Æ¼¼ÏîÄ¿£¨±àºÅ£º02019003£©

Common functions

Last Update: 1900-01-01